$71.18
0.08% yesterday
Nasdaq, Jun 12, 10:00 pm CET
ISIN
US2183521028
Symbol
CORT

Corcept Therapeutics Incorporated. Stock price

$71.18
-0.96 1.33% 1M
+14.86 26.37% 6M
+20.79 41.26% YTD
+38.54 118.08% 1Y
+56.58 387.53% 5Y
+64.52 968.77% 10Y
+67.08 1,636.10% 20Y
Nasdaq, Closing price Thu, Jun 12 2025
-0.06 0.08%
ISIN
US2183521028
Symbol
CORT
Sector
Industry

Key metrics

Market capitalization $7.55b
Enterprise Value $7.22b
P/E (TTM) P/E ratio 64.13
EV/FCF (TTM) EV/FCF 40.77
EV/Sales (TTM) EV/Sales 10.54
P/S ratio (TTM) P/S ratio 11.01
P/B ratio (TTM) P/B ratio 11.04
Revenue growth (TTM) Revenue growth 30.93%
Revenue (TTM) Revenue $685.45m
EBIT (operating result TTM) EBIT $110.87m
Free Cash Flow (TTM) Free Cash Flow $177.16m
Cash position $324.58m
EPS (TTM) EPS $1.11
P/E forward 51.67
P/S forward 8.40
EV/Sales forward 8.04
Short interest 16.06%
Show more

Is Corcept Therapeutics Incorporated. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,845 stocks worldwide.

Corcept Therapeutics Incorporated. Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Corcept Therapeutics Incorporated. forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Corcept Therapeutics Incorporated. forecast:

Buy
100%

Financial data from Corcept Therapeutics Incorporated.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
685 685
31% 31%
100%
- Direct Costs 11 11
41% 41%
2%
675 675
31% 31%
98%
- Selling and Administrative Expenses 315 315
64% 64%
46%
- Research and Development Expense 249 249
23% 23%
36%
113 113
8% 8%
16%
- Depreciation and Amortization 1.73 1.73
80% 80%
0%
EBIT (Operating Income) EBIT 111 111
9% 9%
16%
Net Profit 134 134
14% 14%
20%

In millions USD.

Don't miss a Thing! We will send you all news about Corcept Therapeutics Incorporated. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Corcept Therapeutics Incorporated. Stock News

Neutral
Business Wire
8 days ago
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, presented results from its DAZALS study of dazucorilant in patients with ALS at the European Net...
Neutral
Business Wire
11 days ago
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in ...
Neutral
Investors Business Daily
25 days ago
The top five biotech stocks today have several commonalities. Among them are strong ratings.
More Corcept Therapeutics Incorporated. News

Company Profile

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.

Head office United States
CEO Joseph Belanoff
Employees 500
Founded 1998
Website www.corcept.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today